Advisory Research Inc. maintained its position in TESARO, Inc. (NASDAQ:TSRO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,016 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Advisory Research Inc.’s holdings in TESARO were worth $1,233,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Botty Investors LLC bought a new stake in shares of TESARO in the 2nd quarter valued at about $140,000. Nordea Investment Management AB bought a new stake in shares of TESARO in the 2nd quarter valued at about $167,000. Meeder Asset Management Inc. bought a new stake in shares of TESARO in the 1st quarter valued at about $177,000. Oppenheimer Asset Management Inc. grew its position in shares of TESARO by 3,042.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,430 shares during the last quarter. Finally, BB&T Securities LLC bought a new stake in shares of TESARO in the 2nd quarter valued at about $222,000.
Shares of TESARO, Inc. (NASDAQ TSRO) traded up 1.89% on Friday, reaching $123.52. The company’s stock had a trading volume of 60,694 shares. The company’s market cap is $6.69 billion. TESARO, Inc. has a 12-month low of $106.64 and a 12-month high of $192.94. The company’s 50 day moving average price is $122.29 and its 200 day moving average price is $134.29.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by ($0.30). The firm had revenue of $29.50 million for the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The business’s revenue was down 17.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.28) earnings per share. Analysts forecast that TESARO, Inc. will post ($8.63) EPS for the current fiscal year.
In other TESARO news, VP Grant C. Bogle sold 14,167 shares of TESARO stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $135.00, for a total transaction of $1,912,545.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director James O. Armitage sold 10,000 shares of TESARO stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $117.13, for a total value of $1,171,300.00. Following the sale, the director now directly owns 10,000 shares in the company, valued at $1,171,300. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,692 shares of company stock worth $4,628,976. Insiders own 40.50% of the company’s stock.
A number of research firms have commented on TSRO. Credit Suisse Group set a $190.00 price target on TESARO and gave the company a “buy” rating in a research report on Friday, August 18th. HC Wainwright began coverage on TESARO in a research report on Thursday. They issued a “buy” rating and a $158.00 price target on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $183.00 price target on shares of TESARO in a research report on Thursday, August 10th. Bank of America Corporation reiterated a “buy” rating and issued a $154.00 price target on shares of TESARO in a research report on Tuesday, June 20th. Finally, Wells Fargo & Company reiterated an “outperform” rating and issued a $236.00 price target on shares of TESARO in a research report on Tuesday, June 20th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. TESARO has an average rating of “Buy” and an average price target of $170.19.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO, Inc. (NASDAQ:TSRO).
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.